# Yoon-Koo Kang

Source: https://onco.cc/people/kang-yoon-koo/  
OnCo record `kang-yoon-koo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.

## Summary

Yoon-Koo Kang is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He led ATTRACTION-2, which established the PD-1 antibody nivolumab in late-line gastric cancer in Asia, and SPOTLIGHT, which established zolbetuximab as the first Claudin 18.2-directed therapy, two of the defining gastric cancer studies of the decade. His publications include the ATTRACTION-2 trial of nivolumab in heavily pretreated gastric or gastro-oesophageal junction cancer and the SPOTLIGHT trial of zolbetuximab plus mFOLFOX6 in Claudin 18.2-positive disease. He also led imatinib and other KIT-directed GIST studies.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; gastric cancer and GIST
- Specialisms: Gastric cancer; Gastrointestinal stromal tumour; Immunotherapy; Claudin 18.2

## Sources

- Asan Medical Center: https://eng.amc.seoul.kr
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/), [KIT](https://onco.cc/targets/kit/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Zolbetuximab](https://onco.cc/drugs/zolbetuximab/)
- institutions: [Asan Medical Center](https://onco.cc/institutions/asan-medical-center/)
- trials: [ATTRACTION-2](https://onco.cc/trials/attraction-2/), [SPOTLIGHT & GLOW](https://onco.cc/trials/spotlight-glow/)
- key papers: [SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer](https://onco.cc/key-papers/paper-spotlight-lancet-2023/)

---
JSON: https://onco.cc/api/v1/entities/kang-yoon-koo.json